Advertisement
Valeant
Subscribe to Valeant

The Lead

Bausch and Lomb Acquisition Proving Profitable for Valeant

February 27, 2014 3:51 pm | by Ross Marowits, The Canadian Press | News | Comments

Valeant Pharmaceuticals is seeing more clearly the merits of its acquisition last summer of eye care company Bausch and Lomb and remains on the hunt for another big acquisition this year.                                

Valeant Buying PreCision Dermatology for $475M

February 3, 2014 1:29 pm | News | Comments

Valeant Pharmaceuticals is looking to expand its skin care business by buying PreCision...

FDA Approves Retin-A Microsphere 0.08%

January 31, 2014 9:04 am | News | Comments

Valeant Pharmaceuticals International, Inc. announced today that it has received approval from...

Valeant Pharma Approves $1.5B Securities Buyback

January 22, 2014 11:15 am | by The Associated Press | News | Comments

Canadian drugmaker Valeant Pharmaceuticals said Wednesday it will buy back up to $1.5 billion in...

View Sample

FREE Email Newsletter

Valeant Expects to Make More Acquisitions in 2014

January 7, 2014 1:34 pm | by The Canadian Press | News | Comments

Valeant says it is looking for a big acquisition this year and is aiming to be one of the top five pharma companies in the world by the end of 2016. The Quebec-based company says its goal is to have a market capitalization of $150 billion in two years, meaning it would have to more than triple its current value.

Valeant Pharmaceuticals to Acquire Solta Medical

December 16, 2013 8:11 am | News | Comments

Valeant Pharmaceuticals International has entered into a definitive agreement under which Valeant will acquire all of the outstanding common stock of Solta Medical, Inc. for $2.92 per share in cash, which represents a 40% premium to Solta's closing share price on December 13, 2013, the last trading day prior to announcement, or a transaction value of approximately $250 million.

Valeant Says FDA Approves Luzu Antifungal Cream

November 15, 2013 10:33 am | by The Associated Press | News | Comments

Valeant Pharmaceuticals said Friday that the Food and Drug Administration approved its Luzu cream, which is designed to treat fungal infections. The Canadian drugmaker said Luzu, or luliconazole, is intended to treat athlete's foot, jock itch, and ringworm. It said the cream is indicated for...

Advertisement

Valeant Sees Third Quarter Loss Of $973 Million

October 31, 2013 10:27 am | News | Comments

Valeant Pharmaceuticals lost $973 million in the third quarter, due to a $645 million impairment charge that was tied to an epilepsy treatment, charges of $305 million against the recent Bausch + Lomb acquisition, and $142.5 million to settle some litigation.

Valeant Pharma to Pay Anacor $142.5M in Settlement

October 28, 2013 10:43 am | by The Associated Press | News | Comments

Valeant Pharmaceuticals will pay Anacor Pharmaceuticals $142.5 million in a settlement, the companies said Monday. The payment will be made by Nov. 8, and it will resolve all disputes between Anacor and Valeant. That includes legal proceedings involving Medicis Pharma, which Valeant acquired in...

Anacor Gets $100M Arbitration Ruling from Valeant

October 18, 2013 11:05 am | by The Associated Press | News | Comments

Shares of Anacor Pharmaceuticals climbed Friday after the company said an arbitrator is awarding the company $100 million in a dispute with Canadian drugmaker Valeant Pharmaceuticals. The companies said Valeant was ordered to pay $100 million in damages and will also have to pay costs and...

Valeant Pharma Turns Second Quarter Profit, Raises Guidance

August 7, 2013 8:14 am | by The Associated Press | News | Comments

Valeant Pharmaceuticals turned a second-quarter profit, as acquisitions and sales from emerging markets helped to counter a jump in some expenses. The Canadian company also raised its 2013 earnings forecast. Valeant earned $10.9 million, or 3 cents per share, in the three months that ended June 30.

Valeant to Cut Jobs, Move Bausch and Lomb HQ

July 29, 2013 3:58 pm | News | Comments

Valeant said Monday that it will eliminate as much as 15 percent of its workforce and move Bausch & Lomb's headquarters to New Jersey as part of its $8.7 billion acquisition of the company.In a letter to its own and Bausch & Lomb workers, Valeant said that after the deal closes, it will eliminate between 10 percent and 15 percent of positions companywide. That works out to between 1,850 and 2,775 people.

Advertisement

Valeant Pharma Plans $1.75B Stock Offering

June 17, 2013 4:53 pm | by The Associated Press | News | Comments

Canadian drugmaker Valeant Pharmaceuticals International Inc. said Monday it will sell $1.75 billion in stock to help fund its acquisition of Bausch + Lomb. Valeant did not say how many shares it plans to sell. The company said it plans to raise $1.75 billion before discounts, expenses, and other...

Analysts Raise Estimates on Valeant Pharma

May 29, 2013 1:28 pm | by The Associated Press | News | Comments

Analysts raised their earnings estimates for Valeant Pharmaceuticals International Inc. Wednesday after the Canadian drug developer agreed to buy Bausch + Lomb in a major expansion of its ophthalmology business. THE OPINION: Jefferies & Co. analyst Corey Davis described the deal as "extremely...

Valeant to Buy Bausch + Lomb for $8.7B

May 27, 2013 9:38 am | by LINDA A. JOHNSON,AP Business Writer | News | Comments

Canadian drugmaker Valeant Pharmaceuticals says it will buy eye-health company Bausch + Lomb for $8.7 billion in cash in a massive expansion of its ophthalmology business. Valeant says the deal will help it capitalize on increasing demand for contact lenses and other products because of aging...

Valeant Pharmaceuticals Announces Resignation of Dr. Laurence Paul from Valeant's Board of Directors

May 16, 2013 7:56 am | News | Comments

Valeant Pharmaceuticals International, Inc. announced that Dr. Laurence Paul has resigned from Valeant's Board of Directors due to expanded business, philanthropic, and personal commitments. Dr. Paul was originally elected to Biovail Corporation's Board of Directors in June 2002 where he served in several capacities.

Actavis Buys Vaginal Gel from Valeant for $55M

May 1, 2013 1:40 pm | by The Associated Press | News | Comments

Actavis Inc. said Wednesday it acquired a bacterial vaginosis gel developed by Valeant Pharmaceuticals International Inc. Actavis said it agreed to pay Valeant $55 million for its metronidazole gel product, which has not yet received marketing approval. The total includes both an upfront payment...

Advertisement

Actavis Reaches Agreements with Valeant to Launch Generic Versions of Ziana and Zyclara

April 10, 2013 8:11 am | News | Comments

Actavis and Valeant Pharmaceuticals today announced that Actavis has reached settlement agreements with Medicis Pharmaceutical Corporation, a subsidiary of Valeant, resolving outstanding patent litigation related to Actavis' Abbreviated New Drug Application for Clindamycin and Tretinoin Gel, a generic version of Ziana, as well as Actavis' ANDA for Imiquimod Cream, a generic version of Zyclara.

Merz Pharma Withdraws Obagi Acquisition Offer

April 8, 2013 10:05 am | by The Associated Press | News | Comments

German drugmaker Merz Pharma Group has ended a plan to acquire Obagi Medical Products Inc. after a competitor raised its bid to buy the dermatology products maker. Merz said Monday it is a "disciplined buyer," and it was withdrawing its $22-per-share cash bid for Obagi after Canadian drugmaker Valeant Pharmaceuticals raised its offer last week to $24 per share.

Valeant Says Generic Approval Could Lower Profit

April 4, 2013 9:58 am | by The Associated Press | News | Comments

Valeant Pharmaceuticals International Inc. said Thursday that a newly approved generic version of one of its drugs could significantly reduce its profits this year. Mylan Inc. on Wednesday received final approval from the U.S. Food and Drug Administration to sell the first generic version of...

Valeant Pharmaceuticals and Obagi Medical Products Agree on an Increased Offer Price

April 3, 2013 8:12 am | News | Comments

Valeant Pharmaceuticals International, Inc. today announced that Valeant and Obagi Medical Products, Inc. have executed an amendment to their Agreement and Plan of Merger, dated March 19, 2013.  Pursuant to the amendment, Valeant increased its offer to acquire Obagi from $19.75 to $24.00 per share in cash.

Merz Pharma Offers to Buy Obagi for About $383.5M

April 3, 2013 8:04 am | News | Comments

German drugmaker Merz Pharma Group said Tuesday that it wants to buy dermatology products maker Obagi for about $383.5 million, toping an offer made by Canada's Valeant Pharmaceuticals last month. Merz said it sent a letter to Obagi Medical Products Inc.'s board offering to buy all of the company's stock for $22 per share.

Valeant Pharmaceuticals to Acquire Obagi Medical Products

March 20, 2013 8:39 am | News | Comments

Valeant Pharmaceuticals International, Inc. today announced that it has entered into a definitive agreement under which Valeant will acquire all of the outstanding common stock of Obagi Medical Products, Inc. for $19.75 per share in cash, which represents a 28% premium to Obagi's closing share price on March 19, 2013, the last trading day prior to announcement.

Valeant Pharma Posts 4Q Loss on Deal-Related Costs

February 28, 2013 8:26 am | by The Associated Press | News | Comments

Valeant Pharmaceuticals International Inc. reported a fourth-quarter loss, as acquisition-related costs countered steep revenue growth for the Canadian drugmaker. Valeant focuses on dermatology, neurology and branded generics. Its products include the antidepressant Wellbutrin XL and the blood...

Valeant Pharmaceuticals Acquires U.S. Rights to Targretin from Eisai

February 21, 2013 8:10 am | News | Comments

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., and Valeant Pharmaceuticals International, Inc.  announced today that Valeant has acquired U.S. rights for Targretin (bexarotene) capsules and Targretin (bexarotene) gel 1% from Eisai for $65 million upfront, plus potential contingent payments based on certain milestones

Valeant Pharmaceuticals and Galderma Agree on Revised Agreement Terms

December 6, 2012 3:10 am | News | Comments

Valeant Pharmaceuticals International, Inc. has reached agreement on terms of a revised North American aesthetics arrangement with Galderma S.A.

Valeant Pharmaceuticals Announces New Management Appointments

November 28, 2012 3:12 am | News | Comments

Valeant Pharmaceuticals International, Inc. announced today that Ryan Weldon and Jason Hanson will be named to Valeant's Executive Management Team.

Valeant Pharmaceuticals Announces Management Change

September 14, 2012 4:07 am | News | Comments

Valeant Pharmaceuticals has announced that Rajiv De Silva, Valeant's President and Chief Operating Officer of Specialty Pharmaceuticals, will be leaving the company to pursue other interests.

Valeant Pharmaceuticals to Acquire OraPharma

June 15, 2012 4:20 am | News | Comments

Valeant Pharmaceuticals International, Inc. announced today that Valeant has agreed to acquire OraPharma, a specialty oral health company that develops and commercializes products that improve and maintain oral health, from Water Street Healthcare Partners.

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading